Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction (Q29999973)

20 May 2017

1 reference

D E Gutstein

1

1 reference

20 May 2017

R Krishna

2

1 reference

20 May 2017

D Johns

3

1 reference

20 May 2017

H K Surks

4

1 reference

20 May 2017

H M Dansky

5

1 reference

20 May 2017

S Shah

6

1 reference

20 May 2017

Y B Mitchel

7

1 reference

20 May 2017

J Arena

8

1 reference

20 May 2017

J A Wagner

9

1 reference

20 May 2017

language of work or name

English

0 references

publication date

30 November 2011

1 reference

Clinical Pharmacology & Therapeutics

20 May 2017

published in

1 reference

20 May 2017

volume

91

1 reference

20 May 2017

issue

1

1 reference

20 May 2017

page(s)

109-122

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

20 May 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

22 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Effects of torcetrapib in patients at high risk for coronary events

22 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial

22 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis

22 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins

22 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study

22 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels

22 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly

22 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action

22 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib

22 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels

22 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin

22 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

22 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib

22 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

22 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib

22 May 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke: the PRIME Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Major lipids, apolipoproteins, and risk of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Endothelial and antithrombotic actions of HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

The metabolism and anti-atherogenic properties of HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Future therapeutic directions in reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Emerging HDL-based therapies for atherothrombotic vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Dalcetrapib: a review of Phase II data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Transfers and exchanges of esterified cholesterol between plasma lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes : impact of the degree of triglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

CETP gene variation: relation to lipid parameters and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Association of blood lipids with common DNA sequence variants at 19 genetic loci in the multiethnic United States National Health and Nutrition Examination Survey III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Biochemical characterization of cholesteryl ester transfer protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Biophysical and biochemical approach to locating an inhibitor binding site on cholesteryl ester transfer protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Aldosterone, sodium, and hypertension: lessons from torcetrapib?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Cardiovascular effects of torcetrapib in conscious and pentobarbital-anesthetized dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectromet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Role of bioactivation in drug-induced hypersensitivity reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Genetic variants associated with Lp(a) lipoprotein level and coronary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Model-based development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Safety of anacetrapib in patients with or at high risk for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Applications of 'decisionable' biomarkers in cardiovascular drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

7 January 2021

Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

7 January 2021

Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

7 January 2021

Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

7 January 2021

Dalcetrapib pharmacokinetics and metabolism in the cynomolgus monkey

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

7 January 2021

Effect of diltiazem, a moderate CYP3A inhibitor, on the pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein inhibitor, in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.271

7 January 2021

Identifiers

DOI

10.1038/CLPT.2011.271

1 reference